Methodological Concerns of a Recent Network Meta-analysis Assessing Biologics for Eosinophilic Asthma

Lung. 2019 Feb;197(1):105-106. doi: 10.1007/s00408-018-0183-x. Epub 2018 Nov 30.

Authors

N B Gunsoy¹, D J Bratton², R Alfonso-Cristancho³

Affiliations

¹ Value Evidence and Outcomes, GlaxoSmithKline, Uxbridge, UK. necdet.b.gunsoy@gsk.com.
² Clinical Statistics, GlaxoSmithKline, Uxbridge, UK.
³ Value Evidence and Outcomes, GlaxoSmithKline, Upper Providence, USA.

PMID: 30506167
DOI: 10.1007/s00408-018-0183-x

No abstract available

Publication types

Letter
Comment

MeSH terms

Asthma*
Biological Products*
Humans
Interleukin-13
Interleukin-4
Interleukin-5
Network Meta-Analysis

Substances

Biological Products
Interleukin-13
Interleukin-5
Interleukin-4